FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic
agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional
chemotherapy with the FOLFOX regimen as first-line treatment of chemo-naive metastatic
colorectal cancer patients.
A second primary aim is to evaluate the response rate, safety and tolerability of the
chemotherapy of FOLFOXIRI regimen in this patient population.
Patients will be randomized to two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI Standard arm B: Chemotherapy with FOLFOX